The present invention is generally directed to cannabinoid medical carriers that are effective in the treatment of internal wounds, such as brain or spinal cord injury. One embodiment comprises a application device consisting of a dissolvable biological carrier that contains a cannabinoid, which is readily adsorbed in vivo and is capable of conforming to the size and shape of the surface of the contusion site of a neurological trauma. The various elements of the medical carrier can be saturated with cannabidiol or other phytocannabinoids by diffusion under sterile conditions to achieve medicinal concentrations. The carrier can be applied through open or semi-open surgical procedures, or epidural or by subarachnoid/intrathecal delivery.

The present disclosure provides compositions which may be used as tissue engineering materials, and more particularly xylitol-doped citrate polymer compositions which may be useful as bone grafts.

Disclosed is the preparation of injectable collagen suspensions, to the method for preparing the suspensions, and to the uses thereof, particularly for forming dense collagen matrices.

Hyaluronic acid and silk fibroin or silk fibroin fragments tissue fillers and methods of making and using the same are provided herein. In some embodiments, the disclosure relates to a biocompatible tissue filler comprising silk fibroin or silk fibroin fragments, hyaluronic acid (HA), and polyethylene glycol (PEG) and/or polypropylene glycol (PPG), wherein a portion of the HA is modified or crosslinked by one or more linker moieties comprising one or more of polyethylene glycol (PEG), polypropylene glycol (PPG), and a secondary alcohol, wherein the linker moieties are attached to the HA at one end of the linker.

A novel therapeutic agent delivery system, methods of use and methods of formation thereof are presented. The novel delivery system is comprised of novel nanoparticles capable of at least partially encapsulating a therapeutic agent such as an anesthetic, antimicrobial, growth factor or protein. The nanoparticles are embedded with in a crosslinked hydrogel. The hydrogel can be administered directly to a patient or may be coated onto a device such as a catheter. The delivery system allows for a sustained release of the therapeutic agent over an extended period of time.

Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. Some of the hyaluronic acid-based compositions can include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. Compared to conventional compositions that include lidocaine, some of the hyaluronic acid-based compositions disclosed herein can have an enhanced stability, for example, when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such compositions are also provided.

A medical wound healing accelerator having a body that is removably attached on a fixing pin, of an external fixator for fractures, that is insertable into a bone through skin is provided. The device can further include a plurality of light source units arranged on one surface of the body to emit light and provide a beneficial effect to the wound, and a controller electrically connected to the light source units. An osteomyelitis treatment device having an insert that is insertable into an osteomyelitis part in a human body, and a plurality of light-emitting members provided to the insert to emit light is also provided. The plurality of light-emitting members can be spaced apart from each other, and a part of the insert can be cut or bent to correspond to the shape of the osteomyelitis part.

Described herein are devices used for treating a fistula, along with methods of treatment thereof, and methods of manufacturing the device.

The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.

The present invention describes neutral pH soluble collagen-glycosaminoglycan compositions and methods for augmenting soft tissue defects using the compositions. Soft tissue defects include dermal wrinkles and dermal folds, dermal contour unevenness and laxity and subdermal volume deficiencies. The compositions may also be used for and promoting cellular growth and stimulating tissue regeneration.